Subtopic Deep Dive

Epigenetic Readers in Transcription
Research Guide

What is Epigenetic Readers in Transcription?

Epigenetic readers in transcription are bromodomain and YEATS domain-containing proteins that recognize acetylated histone marks to regulate gene expression, super-enhancers, and cancer cell identity.

Bromodomain proteins like BRD4 bind acetylated lysines on histones to drive transcriptional elongation at super-enhancers (Di Micco et al., 2014, 212 citations). YEATS domain proteins such as ENL interact with similar marks in leukemia (Erb et al., 2017, 313 citations). Over 20 papers from 2012-2020 detail their roles in oncogenesis, with selective BD2 inhibitors emerging for prostate cancer (Faivre et al., 2020, 388 citations).

Curated Papers

Key Challenges

Why It Matters

Dysregulated epigenetic readers like BRD4 maintain cancer cell identity in prostate and rhabdomyosarcoma via super-enhancers (Faivre et al., 2020; Gryder et al., 2017, 312 citations). Mutations in these readers across 1,000 pediatric cancer genomes highlight therapeutic vulnerabilities (Huether et al., 2014, 385 citations). BET inhibitors target BRD4 in MLL-rearranged leukemias, while ENL YEATS disruption blocks acute leukemia transcription (Erb et al., 2017; Winters and Bernt, 2017, 400 citations). These mechanisms drive epigenetic therapies disrupting oncogene addiction.

Key Research Challenges

Selective Bromodomain Inhibition

Pan-BET inhibitors like JQ1 cause toxicity, necessitating BD2-selective agents for prostate cancer (Faivre et al., 2020, 388 citations). Distinguishing BD1 from BD2 functions in transcription remains unresolved (Donati et al., 2018, 681 citations).

YEATS Domain Targeting

ENL YEATS domains drive MLL-fusion leukemia transcription, but small-molecule inhibitors are lacking (Erb et al., 2017, 313 citations). Structural diversity challenges drug design beyond bromodomains.

Super-Enhancer Dependency

PAX3-FOXO1 creates BET-vulnerable super-enhancers in rhabdomyosarcoma, but resistance mechanisms are unclear (Gryder et al., 2017, 312 citations). Integrating with PROTAC degraders for epigenetic readers needs exploration.

Essential Papers

Histone Modifications and Cancer

James E. Audia, Robert M. Campbell · 2016 · Cold Spring Harbor Perspectives in Biology · 1.0K citations

Histone posttranslational modifications represent a versatile set of epigenetic marks involved not only in dynamic cellular processes, such as transcription and DNA repair, but also in the stable m...

BRD4 and Cancer: going beyond transcriptional regulation

Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi · 2018 · Molecular Cancer · 681 citations

Epigenetic modifications of histones in cancer

Zibo Zhao, Ali Shilatifard · 2019 · Genome biology · 561 citations

Abstract The epigenetic modifications of histones are versatile marks that are intimately connected to development and disease pathogenesis including human cancers. In this review, we will discuss ...

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

Amanda Winters, Kathrin M. Bernt · 2017 · Frontiers in Pediatrics · 400 citations

The mixed-lineage leukemia 1 (MLL1) gene (now renamed <i>Lysine [K]-specific MethylTransferase 2A</i> or <i>KMT2A</i>) on chromosome 11q23 is disrupted in a unique group of acute leukemias. More th...

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · 2020 · Nature · 388 citations

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes

Robert Huether, Li Dong, Xiang Chen et al. · 2014 · Nature Communications · 385 citations

Targeting Transcription Factors for Cancer Treatment

Mélanie Lambert, Samy Jambon, Sabine Depauw et al. · 2018 · Molecules · 359 citations

Transcription factors are involved in a large number of human diseases such as cancers for which they account for about 20% of all oncogenes identified so far. For long time, with the exception of ...

Reading Guide

Foundational Papers

Start with Di Micco et al. (2014, 212 citations) for BRD4 super-enhancer mechanism in stem cells, then Huether et al. (2014, 385 citations) for mutation landscape across cancers.

Recent Advances

Faivre et al. (2020, 388 citations) on BD2-selective inhibition; Erb et al. (2017, 313 citations) on YEATS in leukemia; Gryder et al. (2017, 312 citations) on PAX3-FOXO1 BET vulnerability.

Core Methods

ChIP-seq for binding (Gryder et al., 2017); CRISPR YEATS disruption (Erb et al., 2017); BD2 inhibitors via structural design (Faivre et al., 2020); ATAC-seq for chromatin access.

How PapersFlow Helps You Research Epigenetic Readers in Transcription

Discover & Search

Research Agent uses searchPapers('BRD4 super-enhancers cancer') to retrieve 50+ papers like Donati et al. (2018, 681 citations), then citationGraph maps BRD4 → ENL connections from Erb et al. (2017), while findSimilarPapers on Faivre et al. (2020) uncovers BD2 inhibitors.

Analyze & Verify

Analysis Agent applies readPaperContent on Gryder et al. (2017) to extract super-enhancer data, verifyResponse with CoVe checks BRD4 claims against Huether et al. (2014), and runPythonAnalysis performs statistical correlation of mutation frequencies in pediatric cancers using pandas on extracted tables, with GRADE scoring evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in BD2 vs. pan-BET efficacy from Faivre et al. (2020) and Donati et al. (2018), flags contradictions in BRD4 roles; Writing Agent uses latexEditText for figure legends, latexSyncCitations integrates 20 refs, latexCompile generates review PDF, and exportMermaid diagrams BRD4-ENL pathways.

Use Cases

"Analyze mutation rates of BRD4 in 1000 pediatric cancers and plot distribution"

Research Agent → searchPapers('BRD4 mutations pediatric cancer') → Analysis Agent → readPaperContent(Huether et al. 2014) → runPythonAnalysis(pandas groupby on mutation data, matplotlib histogram) → researcher gets CSV plot of BD1/BD2 frequencies.

"Write LaTeX review on BET inhibitors for super-enhancers in rhabdomyosarcoma"

Synthesis Agent → gap detection(Gryder et al. 2017 + Faivre et al. 2020) → Writing Agent → latexEditText(section on degraders) → latexSyncCitations(15 papers) → latexCompile → researcher gets compiled PDF with bromodomain diagram.

"Find GitHub code for BRD4 ChIP-seq analysis in leukemia"

Research Agent → searchPapers('BRD4 ChIP-seq MLL leukemia') → paperExtractUrls(Erb et al. 2017) → paperFindGithubRepo → githubRepoInspect → researcher gets validated NGS pipeline repo with peak-calling scripts.

Automated Workflows

Deep Research workflow scans 50+ papers on 'bromodomain readers transcription cancer', structures report with GRADE-scored sections on BRD4/ENL. DeepScan applies 7-step CoVe to verify super-enhancer claims from Gryder et al. (2017) against Huether et al. (2014). Theorizer generates hypotheses on PROTAC degraders for YEATS domains from Erb et al. (2017) + Faivre et al. (2020).

Try Doxa for Epigenetic Readers in Transcription Research

Frequently Asked Questions

What defines epigenetic readers in transcription?

Bromodomain (BRD4) and YEATS (ENL) proteins that bind acetylated histones to activate super-enhancer transcription (Di Micco et al., 2014; Erb et al., 2017).

What methods target these readers?

BET inhibitors (JQ1), BD2-selective (ABBV-744 in Faivre et al., 2020), YEATS disruptors (Erb et al., 2017); ChIP-seq maps binding (Gryder et al., 2017).

What are key papers?

Donati et al. (2018, 681 citations) on BRD4 beyond transcription; Faivre et al. (2020, 388 citations) on BD2 inhibition; Erb et al. (2017, 313 citations) on ENL YEATS.